[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] [@laburnum1000](/creator/twitter/laburnum1000) "@novonordisk Novo Nordisk is acquiring Akero Therapeutics for up to $XXX billion gaining its Phase X FGF21 analogue efruxifermin (EFX) to strengthen Novos MASH (fatty liver disease) portfolio and expand beyond obesity and diabetes into liver-metabolic care" [X Link](https://x.com/laburnum1000/status/1976460375597121672) [@laburnum1000](/creator/x/laburnum1000) 2025-10-10T01:30Z 1572 followers, XXX engagements "@novonordisk Novo acquires Omeros clinical candidate zaltenibart (OMS906) a MASP-3 inhibitor for rare blood and kidney diseases. 💉 The deal is worth up to USD XXX billion including USD XXX million upfront. Strengthening Novos focus on the complement system and rare diseases. #biotech" [X Link](https://x.com/laburnum1000/status/1978463772688736733) [@laburnum1000](/creator/x/laburnum1000) 2025-10-15T14:11Z 1572 followers, XXX engagements "@INV44X @novonordisk Novo is diversifying beyond diabetes and obesity-investing in rare disease innovation with strong scientific rationale. Zaltenibart targets the complement system a hot area in biotech with multi-billion potential. Smart long-term move short-term buybacks" [X Link](https://x.com/laburnum1000/status/1978504904957194422) [@laburnum1000](/creator/x/laburnum1000) 2025-10-15T16:55Z 1572 followers, XX engagements "@INV44X @novonordisk By 2030 $NVO might be the case study they teach MBA students as how not to do it 🤷♂😂" [X Link](https://x.com/laburnum1000/status/1979192938291749286) [@laburnum1000](/creator/x/laburnum1000) 2025-10-17T14:29Z 1570 followers, XXX engagements "@INV44X @novonordisk Good idea maybe we can even IPO the therapy sessions while were at it 🤷♂" [X Link](https://x.com/laburnum1000/status/1979194333086576977) [@laburnum1000](/creator/x/laburnum1000) 2025-10-17T14:34Z 1570 followers, XX engagements "@Tarakb0 @FoxNews @NEWSMAX @thehill @nypost @EpochTimes Thank you dear Tara.🙏 Let one voice rise across every city of Iran: #LongLiveTheShah 👇" [X Link](https://x.com/laburnum1000/status/1980842732768952655) [@laburnum1000](/creator/x/laburnum1000) 2025-10-22T03:44Z 1566 followers, XX engagements "Exciting Looking forward to seeing how Novo Nordisks oral semaglutide advances obesity treatment and whats next in their pipeline. 🚀📊" [X Link](https://x.com/laburnum1000/status/1980891967669301666) [@laburnum1000](/creator/x/laburnum1000) 2025-10-22T07:00Z 1565 followers, XXX engagements "@INV44X Funny take yet NVO keeps breaking records while others just complain.🔥" [X Link](https://x.com/laburnum1000/status/1980927416957796689) [@laburnum1000](/creator/x/laburnum1000) 2025-10-22T09:21Z 1567 followers, XX engagements "@INV44X Youll have to accept the fact that $NVO keeps winning while the haters keep whining. 📈💪" [X Link](https://x.com/laburnum1000/status/1980928293177319856) [@laburnum1000](/creator/x/laburnum1000) 2025-10-22T09:24Z 1567 followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@laburnum1000
"@novonordisk Novo Nordisk is acquiring Akero Therapeutics for up to $XXX billion gaining its Phase X FGF21 analogue efruxifermin (EFX) to strengthen Novos MASH (fatty liver disease) portfolio and expand beyond obesity and diabetes into liver-metabolic care"
X Link @laburnum1000 2025-10-10T01:30Z 1572 followers, XXX engagements
"@novonordisk Novo acquires Omeros clinical candidate zaltenibart (OMS906) a MASP-3 inhibitor for rare blood and kidney diseases. 💉 The deal is worth up to USD XXX billion including USD XXX million upfront. Strengthening Novos focus on the complement system and rare diseases. #biotech"
X Link @laburnum1000 2025-10-15T14:11Z 1572 followers, XXX engagements
"@INV44X @novonordisk Novo is diversifying beyond diabetes and obesity-investing in rare disease innovation with strong scientific rationale. Zaltenibart targets the complement system a hot area in biotech with multi-billion potential. Smart long-term move short-term buybacks"
X Link @laburnum1000 2025-10-15T16:55Z 1572 followers, XX engagements
"@INV44X @novonordisk By 2030 $NVO might be the case study they teach MBA students as how not to do it 🤷♂😂"
X Link @laburnum1000 2025-10-17T14:29Z 1570 followers, XXX engagements
"@INV44X @novonordisk Good idea maybe we can even IPO the therapy sessions while were at it 🤷♂"
X Link @laburnum1000 2025-10-17T14:34Z 1570 followers, XX engagements
"@Tarakb0 @FoxNews @NEWSMAX @thehill @nypost @EpochTimes Thank you dear Tara.🙏 Let one voice rise across every city of Iran: #LongLiveTheShah 👇"
X Link @laburnum1000 2025-10-22T03:44Z 1566 followers, XX engagements
"Exciting Looking forward to seeing how Novo Nordisks oral semaglutide advances obesity treatment and whats next in their pipeline. 🚀📊"
X Link @laburnum1000 2025-10-22T07:00Z 1565 followers, XXX engagements
"@INV44X Funny take yet NVO keeps breaking records while others just complain.🔥"
X Link @laburnum1000 2025-10-22T09:21Z 1567 followers, XX engagements
"@INV44X Youll have to accept the fact that $NVO keeps winning while the haters keep whining. 📈💪"
X Link @laburnum1000 2025-10-22T09:24Z 1567 followers, XXX engagements
/creator/twitter::1558391889681842181/posts